Graeme Bell Net Worth

The estimated Net Worth of Graeme Bell is at least $433 Тысяча dollars as of 28 March 2018. Graeme Bell owns over 8,000 units of Intellia Therapeutics Inc stock worth over $433,136 and over the last 8 years Graeme sold NTLA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Graeme Bell NTLA stock SEC Form 4 insiders trading

Graeme has made over 1 trades of the Intellia Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Graeme exercised 8,000 units of NTLA stock worth $107,840 on 28 March 2018.

The largest trade Graeme's ever made was exercising 8,000 units of Intellia Therapeutics Inc stock on 28 March 2018 worth over $107,840. On average, Graeme trades about 1,333 units every 0 days since 2017. As of 28 March 2018 Graeme still owns at least 21,400 units of Intellia Therapeutics Inc stock.

You can see the complete history of Graeme Bell stock trades at the bottom of the page.

What's Graeme Bell's mailing address?

Graeme's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA, 02139.

Insiders trading at Intellia Therapeutics Inc

Over the last 8 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela и Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.

What does Intellia Therapeutics Inc do?

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the

Complete history of Graeme Bell stock trades at Intellia Therapeutics Inc

Intellia Therapeutics Inc executives and stock owners

Intellia Therapeutics Inc executives and other stock owners filed with the SEC include:

• Laura Sepp-Lorenzino,
  Executive Vice President, Chief Scientific Officer
• Andrew Schiermeier,
  Chief Operating Officer, Executive Vice President
• Dr. John M. Leonard,
  Pres, CEO & Director
• John Leonard,
  President, Chief Executive Officer, Director
• José E. Rivera,
  Exec. VP, Gen. Counsel & Company Sec.
• Jose Rivera,
  Executive Vice President, General Counsel
• Dr. Laura Sepp-Lorenzino,
  Exec. VP & Chief Scientific Officer
• Glenn G. Goddard,
  Exec. VP, CFO & Treasurer
• Frederick Cohen,
  Independent Director
• Glenn Goddard,
  Chief Financial Officer, Executive Vice President
• Dr. David Lebwohl M.D.,
  Exec. VP & Chief Medical Officer
• Perry Karsen,
  Independent Director
• Caroline Dorsa,
  Independent Director
• Frank Verwiel,
  Independent Chairman of the Board
• Jesse Goodman,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Lina Li,
  Senior Manager, Investor Relations
• John Crowley,
  Independent Director
• David Lebwohl,
  Executive Vice President, Chief Medical Officer
• Dr. Rodolphe Barrangou M.B.A., Ph.D.,
  Founder & Member of Scientific Advisor Board
• Dr. Jennifer A. Doudna Ph.D.,
  Founder & Member of Scientific Advisor Board
• Dr. Rachel E. Haurwitz Ph.D.,
  Co-Founder
• Dr. Derrick J. Rossi,
  Founder & Member of Scientific Advisor Board
• Dr. Jennifer A. Doudna,
  Founder & Member of Scientific Advisor Board
• Andrew May Ph.D.,
  Founder and Member of Scientific Advisor Board
• Rachel Haurwitz Ph.D.,
  Co-Founder
• Nessan Bermingham Ph.D.,
  Founder & Member of Scientific Advisor Board
• William J Chase,
  
• Fred E Cohen,
  
• Muna Bhanji,
  
• Carl L Gordon,
  Director
• Institutes For Bio Medical ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Graeme Bell,
  EVP, Chief Financial Officer
• Venture Associates Ix, L.P....,
  
• Nicole Heifner,
  SVP, Accounting
• Thomas M. Barnes,
  SVP, R&D eXtellia
• Therapeutics Holdco, Llc Ca...,
  
• Nessan Bermingham,
  President & CEO
• David V Morrissey,
  SVP, Platform & Delivery Tech
• Venture Fund Ix, L.P.Atlas ...,
  
• Holdings (Private) Ltd Full...,
  
• Rachel E. Haurwitz,
  Director
• Bros. Advisors Lpbaker Feli...,
  
• Georgia Keresty,
  
• Brian Goff,
  
• Moncef Slaoui,
  Director
• James Basta,
  EVP, General Counsel
• Biosciences, Inc. Caribou,
  
• Derek Hicks,
  EVP, Chief Business Officer
• Eliana Clark,
  EVP, Chief Technical Officer
• Michael P Dube,
  VP, PAO and Interim PFO
• Edward J Iii Dulac,
  EVP, Chief Financial Officer